NASDAQ: MBXMbx Biosciences Inc Stock
$7.64+0.02 (+0.26%)
Updated Apr 21, 2025
MBX Price
$7.64
Fair Value Price
$1.54
Market Cap
$255.36M
52 Week Low
$4.81
52 Week High
$27.50
P/E
-1.31x
P/B
0.99x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.92M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$55M
Beta
1.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MBX Overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MBX
Ranked#209 of 462
Ranked#209 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important MBX news, forecast changes, insider trades & much more!
MBX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBX ($7.64) is overvalued by 394.84% relative to our estimate of its Fair Value price of $1.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MBX ($7.64) is not significantly undervalued (394.84%) relative to our estimate of its Fair Value price of $1.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MBX due diligence checks available for Premium users.
Valuation
MBX fair value
Fair Value of MBX stock based on Discounted Cash Flow (DCF)
Price
$7.64
Fair Value
$1.54
Overvalued by
394.84%
MBX ($7.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBX ($7.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.31x
Industry
-184.27x
Market
27.14x
MBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
4.04x
MBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.6M
Profit Margin
0%
MBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$268.5M
Liabilities
$11.1M
Debt to equity
0.04
MBX's short-term assets ($267.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBX's short-term assets ($267.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.0M
Investing
-$67.3M
Financing
-$132.0k
MBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBX vs Biotech Stocks
Mbx Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.